TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants With Gastro Esophageal Reflux Disease One Year After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Absolute values and changes over time of hematology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Absolute values and changes over time of urinalysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Absolute values and changes over time of vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute values and changes over time of ECG intervals and ECG rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: early neurological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bone Density Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration changes of inflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ischaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: marginal soft tissue levels rebound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients effectively treated for intertrigo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in the number of hours spent in OFF time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average bradykinesia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on SF 36 physical health survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Combined imaging exam orders per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Experiencing Death Due to Adverse Events
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Experiencing Adverse Events of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Total cost of accessory use and pathology specimen costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Unsafe Events for Each Participant
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Mayo-Portland Participation Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline methacholine bronchoprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accumulative Patency Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Hour 0 to 24 (AUC [0-24])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Elimination Half-life (t½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Postoperative Opioid Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: gas flow over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fraction in inspired oxygen (FiO2) over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biomarkers for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Successful First Attempt Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Post Operative Morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Maintenance of Immune function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MSFC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: DAM score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: vascular unloading time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in Trans-Epidermal Water-Loss (TEWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants with Negative Minimal Residual Disease (MRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Sustained MRD Negative Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolite levels in endometrial samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity and specificity of DBS for SARS-CoV-2 antibody detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall rates of significant toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom From Composite of Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Conversion to Open Surgical Repair
Endpoint domain: Mortality/survival
Primary endpoint: Freedom From Reintervention on Iliac Branch Component (IBC) or Internal Iliac Component (IIC)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of pathologically confirmed malignant supraclavicular lymph node
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Malnutrition-inflammation score (MIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phosphorus levels control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weighted Average Change From Baseline in Mesopic, High Contrast Uncorrected Near Visual Acuity (UNVA) Letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak aFXa levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in range of motion on goniometer at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline in flexibility on tape measure at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline in pulmonary function test on the spirometer at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in pain on the Numeric Rating Scale at 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Proportion of patients receiving recommended measures to prevent surgical site infections
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with adverse event during immunotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: CT perfusion parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Aortic Vascular Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in distribution volume (VT)%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of circulating tumor DNA (ctDNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Peak post-operative troponin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intra-Papillary Capillary Loop (IPCL) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Suicidal Ideation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anatomic Result at 4-Months post-operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Palliative care Referrals
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of palliative first-line chemotherapy cycles administered
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Informal caregiver-reported outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients who initiate treatment after first visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Performance Status Scale for Head and Neck Cancer Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Oral Intake Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Amplitude of forearm cutaneous vasodilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucagon Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Frequency and degree of hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum/plasma markers of hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor perfusion using dynamic positron emission tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal maneuvers in macular membrane dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to onset of a ≥ 30% decrease in eGFR from baseline or ESRD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Kidney Graft Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Patient-clinician communication scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived lung cancer stigma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of Life (General health)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Fatal or Life-threatening Major Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Pupillary reflexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharmacological effect of disulfiram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Achieving Disease Control Rate at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulcer healing at 14 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Important Changes in Electrocardiograms (ECGs) From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Clinically Important Changes in Vital Signs From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implantation success based on VARC-2 criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in elevated platelet counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PCR adjusted parasitological cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uncorrected distance visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uncorrected intermediate distance visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and Frequency of Revisions
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and Frequency of Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and Frequency of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically relevant changes in laboratory parameters: coagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of clinically relevant changes (abnormalities) in laboratory parameters: biochemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of acute graft versus host disease (GVHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: overall survival after HSCT
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Anti-hGH Binding Antibody Formation
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Anti-hGH Neutralizing Antibody Formation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Local Tolerability Events
Endpoint domain: Adverse events/effects
Primary endpoint: Patient compliance with the web-application
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient satisfaction with the application
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of early coating on the struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of covered struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of stents with ≥3% of uncovered struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of the duration of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of ETV XR tablet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dentine hypersensitivity score to stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure related time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Nocturnal Intraocular Pressure Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractional flow reserve at maximal hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of episodes of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of episodes of pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reversibility of dysmotility after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Specificity of Bladder Cancer Detection Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants Who Achieved a Complete or Partial Renal Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Accuracy of placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the time curve from time zero to 24 hours postdose (AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale (VAS) reduction from baseline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Autobiographical memory test (TEMPau) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in Percent Predicted Peak Expiratory Flow (PEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Base deficit (umbilical artery)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of Mirabegron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise echo Doppler
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentration of miRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANSS Positive Subscale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Culture-Confirmed Bacterial Eradication of Neisseria Gonorrhoeae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Agreement between invasive and non-invasive measures of LVEDP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: symptom-free or steroid-free remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake Value of C11-choline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Lesions Showing C11-Choline Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of PPFP counseling
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical competency of service providers in providing all modern FP methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the trial treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Cost of diagnostics per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Apnoea-Hypopnoea Index (AHI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: WPPSI-R vocabulary subdomain score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: adequate exposure for transoral resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time from surgery to first flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time from surgery to first defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage of skin pigmentation in the treated area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Weighted mean glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in number of inflamed joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CHAQ, child health assessment questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in assessment of pain: visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparative accuracy of PT/INR measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: COVID-19 IgG antibodies median
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of Epworth Sleepiness Scale (ESS) score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with laboratory abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with change from baseline in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quitting smoking after 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expired breath CO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Corrected Flow Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline subjective sleep quality at 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from baseline physical activity at 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline objective sleep quality at 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Accuracy of rubidium-82 PET MPI for CAD diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting 12-lead electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence rate of inpatient RSV-associated acute respiratory illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Events leading to worsening cardiorespiratory status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Mutational Load (ML)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Treatment Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Response at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Treatment Failure Through 48 Weeks of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Gait Deviation Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Inappropriate Transthoracic Echocardiograms ordered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Urine culture results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Glucose concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycated hemoglobin concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes